Novel therapies and new targets of treatment for familial hypercholesterolemia

This publication has 18 references indexed in Scilit:

• Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
  The American Journal of Cardiology, 2010
• Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
  Journal of Lipid Research, 2010
• Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
  Journal of the American College of Cardiology, 2010
• Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
  The Lancet, 2010
• Development of Apolipoprotein B Antisense Molecules as a Therapy for Hyperlipidemia
  Current Atherosclerosis Reports, 2009
• Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development
  Endocrinology and Metabolism Clinics of North America, 2009
• Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
  Clinical Pharmacokinetics, 2009
• Novel nonstatin strategies to lower low-density lipoprotein cholesterol
  Current Atherosclerosis Reports, 2008
• Antisense apolipoprotein B therapy: where do we stand?
  Current Opinion in Lipidology, 2007
• Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B
  Circulation, 2006